ALK F1174L

ALK F1174L在成神经细胞瘤、非小细胞肺癌（NSCLC）和其他类型的癌症中被观察到复发。含有这种突变的神经母细胞瘤细胞对低剂量的环唑单抗有抵抗力。然而，在细胞系研究中，增加剂量可以克服这种阻力。TAE684也被证明对非小细胞肺癌和神经母细胞瘤F1174L细胞有效。
ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.